Stock 4591 RIBOMIC INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ribomic Inc.

Equities

4591

JP3974850004

Market Closed - Japan Exchange
Other stock markets
 07:00:00 16/05/2024 BST 		5-day change 1st Jan Change
84 JPY -1.18% Intraday chart for Ribomic Inc. 0.00% -22.22%
03-07 Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc. CI
02-20 Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc. CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)
BU
RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis
PU
Ribomic : 【Delayed】RIBOMIC Announces Publication Highlighting Novel Approach to Generate Aptamer using AI in the Nature Computational Science
PU
RIBOMIC : Announces Completion of IND submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia
PU
RIBOMIC : Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration
PU
RIBOMIC : Announces Presentation Materials of the 40th Annual J.P. Morgan Healthcare Conference
PU
RIBOMIC : Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration
PU
RIBOMIC : Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference
PU
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
BU
RIBOMIC : Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
PU
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2021(Based on Japanese GAAP)
PU
RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting
BU
RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet AMD at the Retina Society 2021 Meeting
PU
RIBOMIC : Completes Patient Enrollment of its US Phase 2 Open-Label Extension Clinical Trial of RBM-007 for wet AMD (RAMEN Study)
PU
RIBOMIC : Completes Patient Enrollment of its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (TOFU Study)
PU
RIBOMIC : Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in treatment naive wet AMD Patients
PU
RIBOMIC : Announces Termination of MTA with The Pritzker Neuropsychiatric Disorders Research Consortium
PU
Ribomic : Summary of Non-Consolidated Financial Results for the Year Ended March 31, 2021 (Based on Japanese GAAP)
PU
RIBOMIC : Announces Completion of its Phase I Trial of RBM-007 for the Treatment of Achondroplasia
PU
RIBOMIC : Announces Publication of a Research Paper on an Aptamer Creation Platform Technology for Membrane Receptor GPCR
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4591 Stock
  4. News Ribomic Inc.
  5. Press Releases